Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Public ClinicalTrials.gov record NCT03651128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
Study identification
- NCT ID
- NCT03651128
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 386 participants
Conditions and interventions
Conditions
Interventions
- bb2121 Biological
- Daratumumab Drug
- Pomalidomide Drug
- Dexamethasone Drug
- Bortezomib Drug
- Ixazomib Drug
- Lenalidomide Drug
- Carfilzomib Drug
- Elotuzumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2019 (Actual)
- Primary completion
- Apr 13, 2026 (Actual)
- Completion
- Apr 13, 2026 (Actual)
- Last update posted
- Jun 22, 2026
2019 – 2026
United States locations
- U.S. sites
- 36
- U.S. states
- 24
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 109 | Birmingham | Alabama | 10016 | — |
| Local Institution - 141 | Scottsdale | Arizona | 85259 | — |
| Local Institution - 145 | Los Angeles | California | 90048 | — |
| Local Institution - 122 | Los Angeles | California | 90095 | — |
| Local Institution - 124 | Palo Alto | California | 94304 | — |
| Local Institution - 142 | Aurora | Colorado | 80045 | — |
| Local Institution - 108 | Jacksonville | Florida | 32224 | — |
| Local Institution - 102 | Tampa | Florida | 33612 | — |
| Local Institution - 131 | Atlanta | Georgia | 30322 | — |
| Local Institution - 140 | Atlanta | Georgia | 30342 | — |
| Local Institution - 139 | Chicago | Illinois | 60611 | — |
| Local Institution - 100 | Indianapolis | Indiana | 46202-528 | — |
| Local Institution - 112 | Westwood | Kansas | 66205-2003 | — |
| Local Institution - 104 | Baltimore | Maryland | 21201-1595 | — |
| Local Institution - 134 | Boston | Massachusetts | 02114 | — |
| Local Institution - 123 | Boston | Massachusetts | 02215 | — |
| Local Institution - 120 | Ann Arbor | Michigan | 48109-5936 | — |
| Local Institution - 125 | Rochester | Minnesota | 55905-0001 | — |
| Local Institution - 114 | St Louis | Missouri | 63110 | — |
| University Of Nebraska | Omaha | Nebraska | 68198-7680 | — |
| Local Institution - 138 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 119 | New York | New York | 10029 | — |
| Local Institution - 115 | New York | New York | 10065 | — |
| Local Institution - 135 | New York | New York | 10065 | — |
| Local Institution - 113 | Durham | North Carolina | 27705 | — |
| Local Institution - 111 | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 110 | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 101 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 106 | Nashville | Tennessee | 37203 | — |
| Local Institution - 118 | Dallas | Texas | 75246 | — |
| Local Institution - 103 | Dallas | Texas | 75390 | — |
| Local Institution - 132 | Houston | Texas | 77030 | — |
| Local Institution - 136 | Salt Lake City | Utah | 84112 | — |
| Local Institution - 105 | Seattle | Washington | 98104 | — |
| Local Institution - 107 | Madison | Wisconsin | 53792 | — |
| Froedtert Hospital BMT Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03651128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03651128 live on ClinicalTrials.gov.